+ more

Amman, 28 January 2014 - Hikma Pharmaceuticals (LSE:HIK) (NASDAQ Dubai: HIK), the fast growing multinational pharmaceutical group, today announces that it has entered into a new service agreement with PrimeVigilance,a leading international company that provides pharmacovigilance (PV) and medical information services, to gain access to top quality and global-scale PV services.

Pharmacovigilance or Drug Safety, is the pharmacologicalscience relating to the monitoring, detection and prevention of adverse effects with pharmaceutical products.

This agreement will enable Hikma to globalize all its PVoperations across its worldwide group of companies, and assist Hikma in covering all the regulatory and scientific elements of PVrequired by health authoritiesin different countries.

In addition, Hikma will better monitor and evaluate the benefit-risk balance of its products, and will be more compliant with the highest standards of quality, international regulations, and codes of best practices. The agreement will also re-enforceHikma's commitment to compliance with laws & regulations.

Mr. Said Darwazah, Hikma Pharmaceuticals' CEO,said "I am pleased to announce this partnership with PrimeVigilance, whichwill enable us to maintain our highest standards of quality. Through this partnership, wefulfillour commitmentto the safety of our patients wherever we operate in compliance with all applicable laws and regulations."

Mr. Neil Clark, PrimeVigilance CEO, said "We are very pleased to be working with Hikma and providing a range of important safety services to support their fast-growing, international operations."

-END-

distributed by